Lana Morrow, Ph.D.

Founder and CEO

Dr. Lana Morrow, Ph.D. is an award winning functional medicine neuroscientist, Founder, CEO, and creator of THINK system, and is an expert in dopamine, executive functions, and neurotechnology.  She has worked with students, diplomats, actors, European royalty, and Fortune 500 CEOs in Manhattan, Paris and Rome.

Engaging with students and professionals, Dr. Morrow improves their attention, mood, and academic and sports performance. She has been featured in the New York Times, Panorama, RAI 2 and various other media. Known for her innovative and caring approach, Dr. Morrow helps many achieve optimal potential with advanced approaches.

Dr. Morrow founded THINK Interfaces in order to create non-invasive, non-pharmacological methods for remediation of attentional and movement related disorders. She is passionate about helping her clients elevate their cognitive performance, longevity and memory. She is a Galileo2000 Award winner, and recognized as a pioneer in brain computer interfaces and neuroeconomy.   

Dr. Morrow earned a doctoral degree in cognitive neuroscience from Sapienza University in Rome, Italy, was a visiting researcher at the Sorbonne in Paris, and completed her post-doctoral training at Mount Sinai Hospital in New York City, performing EEG-based brain mapping techniques in dopamine research and at Columbia Presbyterian hospital.  Her skills also include treatment of learning disabilities, attention deficit disorder and the differential diagnosis of complex brain disorders. As a neuroscientist, she conducts research collaborations with major universities in Europe and the United States.

Moses Chao, Ph.D.

White House Scientific Advisor
Professor of Molecular Neurobiology, NYU
President of Think Scientific Board
Past President of Society for Neuroscience

Moses V. Chao received his BA degree in biochemistry from Pomona College and his PhD from UCLA in 1980. He carried out postdoctoral research at Columbia University with Richard Axel, before joining the faculty at Cornell Medical School in 1984. In 1998, he moved to NYU School of Medicine, where he is presently Professor of Cell Biology, Physiology & Neuroscience and Psychiatry. His laboratory discovered and defined the genes encoding the NGF receptor. His research interests are to define the mechanisms used by trophic factors to change synaptic plasticity and prevent neurodegenerative diseases, such as Huntington’s and Alzheimer’s diseases. He has served as Senior Editor for the Journal of Neuroscience for eleven years and also as an editor for Developmental Neurobiology and Molecular and Cellular Neuroscience. He has also been a member of the Scientific Advisory Boards for the Simons Foundation, the Glaucoma Research Foundation, St. Jude’s Children’s Research Hospital. He has served as Chair of the Christopher and Dana Reeve Foundation, Board of Scientific Counselors for NICHD, the New York State Spinal Cord Research Injury Board and the European Brain Research Foundation. He was named a Fellow of the AAAS in 2007 and was a recipient of a Zenith Award from the Alzheimer’s Association; the Jacob Javits Neuroscience Investigator Award; and a Guggenheim Fellowship. In 2012, Chao was elected President of the Society for Neuroscience, which represents a nonprofit organization of 42,000 scientists and physicians who study the brain and nervous system.

Jean Christophe Corvol, M.D., Ph.D.

Assistant Professor in Neuropharmacology
APHP, CRicm, UPMC, Inserm UMR_S975/CNRS UMR 7225, Pitié-Salpêtrière Hospital
ICM Institute for Brain and Spine, Paris

Jean-Christophe Corvol (JCC) is assistant professor in neuro-pharmacology at the Pitié-Salpêtrière Hospital. He has an MD in Neurology (2003), a PhD in neurosciences (2005) and he did a post-doc in the field of trancriptomic biomarkers (2006-2007, Molecular Neurogenetic Laboratory, UCSF, San Francisco). Since 2008, JCC heads the Neurosciences Clinical Research Center at the Pitié-Salpêtrière Hospital (APHP, INSERM, CIC-9503) and he is a principal investigator in the research team of Alexis Brice (CR-ICM).

JCC is a member of the French Society of Pharmacology, the French Society of Neurology, and the Movement Disorder Society. He is member of the scientific board of the European College of Neuropsychopharmacology, the French Association for Parkinson’s Disease, and the French Foundation for Brain Research.
His research is focused on drug development, biomarkers and pharmacogenetics of Parkinson’s disease. He has published more than 40 papers in international journals.

Francesco Boccalatte, Ph.D.

Fellow NYU School of Medicine
Ph.D. in Cancer Biology and Biotherapy
NYU Clinical and Translational Science Institute (CTSI) Career development award
American-Italian Cancer Foundation (AICF) Post-doctoral research fellowship

Dr. Boccalatte was trained in Molecular Oncology and Clinical Biochemistry the Department of Pathology at the University of Turin, Italy. During his undergraduate studies and residency he identified novel markers involved in lymphoma cells resistance to chemotherapy. He then moved to San Raffaele Hospital in Milan, Italy, where he got a Ph.D. in Cancer Biology and Biotherapy. During his training in Milan, he discovered new epigenetic regulators of hematopoietic stem cells. He also characterize epigenetic factors that contribute to leukemia development and maintenance. He is currently a fellow at NYU School of Medicine, where he studies pediatric leukemias, with a particular focus on cases that do not respond to standard chemotherapy, in order to identify patients that could benefit from new experimental therapies.